Maxim Biotech, Inc., a company dedicated to the development of high quality, IVD and POC testing solutions, announced plans to produce and market as many as 3 million Maxim SARS-CoV-2 Rapid Antigen Diagnostic Tests (patent pending) by the end of the year. The test was developed in conjunction with the National Institutes of Health (NIH) through the Rapid Acceleration of Diagnostics (RADxSM) initiative.